About Patrick Ryan

Patrick Ryan has invested in stocks and traded options for more than a decade. He specializes in growth stocks, with a particular focus on those in the technology and entertainment sectors. Patrick began writing for StockNews.com in 2019. His mission is to pinpoint growth stocks trading at attractive prices. This requires a focus on the fundamentals including in-depth qualitative and quantitative analysis. Patrick often abides by a contrarian market strategy as he analyzes investment opportunities with irreverence for conventional logic. This often leads to finding hidden gems with tremendous long term upside potential.


Recent Articles By Patrick Ryan

: CERN |  News, Ratings, and Charts

Should You Buy the Dip in Cerner?

While health information company Cerner (CERN) rebounded last year after the pandemic market drop, the stock has been trending down since late January. This has created an attractive multiple, but is it worth holding now? Read more to find out.
: EOG |  News, Ratings, and Charts

Think Oil Prices Will Continue to Rally? Consider Buying These 2 Top-Rated Energy Stocks 

Oil prices have recovered the bulk of their coronavirus losses, yet many energy stocks remain undervalued relative to their pre-coronavirus prices. Petrochina (PTR) and EOG Resources (EOG) are two of the top energy stocks.
: UNFI |  News, Ratings, and Charts

Up 114% YTD, Will United Natural Foods Continue to Rally?  

United Natural Foods (UNFI) has done well this year as people may spend more on organic food if they are feeling wealthier. This is likely due to a strong housing and stock market.
: NVS |  News, Ratings, and Charts

3 New Strong Buy-Rated Stocks That Belong in Your Portfolio

With market volatility continuing, it can be tough to find good stocks to buy. That's where our proprietary POWR Ratings can help. Strong Buy and Buy stocks are more likely to outperform the market, which is why investors should consider recently upgraded stocks such as Novartis (NVS), Zumiez (ZUMZ), and Lifetime Brands (LCUT).
: DBX |  News, Ratings, and Charts

Up 20% in 2021, Will Dropbox Continue to Rally?  

Dropbox (DBX) is up 20% so far in 2021. Will this outperformance continue or will it decline like many other tech stocks. Patrick Ryan gives his take.
: MVIS |  News, Ratings, and Charts

3 Downgraded Stocks to Consider Selling

The market is starting to chop after the S&P 500 made it back to new highs. Geron (GERN), Gladstone (LAND), and Microvision (MVIS) are three stocks recently downgraded by the POWR Ratings that investors should consider selling.
: WPM |  News, Ratings, and Charts

3 Gold Stocks Wall Street Loves  

Newmont Corp. (NEM), Wheaton Precious Metals (WPM), and Kirkland Lake Gold (KL) are three gold stocks that Wall Street is bullish on. Given gold's more than 15% decline from recent highs, is it time to increase exposure?
: CRM |  News, Ratings, and Charts

2 Tech Stocks Goldman Sachs Just Added to Their Conviction Buy List  

CRM (CRM) and Microsoft (MSFT) are two of the leading cloud computing stocks. Both have underperformed the market in recent months although earnings momentum is solid. Patrick Ryan breaks down which is the better buy.
: KLIC |  News, Ratings, and Charts

Will the Rally in Kulicke & Soffa Industries Stock Continue After Doubling in Six Months?

Due to the pandemic and a trade war between the U.S. and China, there is a shortage for semiconductor chips. This has been a boon for chip companies such as Kulicke & Soffa (KLIC). But will the stock continue to rise? Read more to find out.
: ABBV |  News, Ratings, and Charts

AbbVie vs. Bristol Myers Squibb: Which Pharmaceutical Stock is a Better Buy?

With the greatest health crisis in more than 100 years, pharmaceutical stocks have been the talk of Wall Street. But which ones are the best to invest in now? Patrick Ryan compares AbbVie (ABBV) to Bristol Myers Squibb (BMY) to see which is a better buy.
Page generated in 1.4354 seconds.